1,353
Views
49
CrossRef citations to date
0
Altmetric
Research Article

Revisiting the nanoformulation design approach for effective delivery of topotecan in its stable form: an appraisal of its in vitro Behavior and tumor amelioration potential

, , , , , , & show all
Pages 2827-2837 | Received 16 Aug 2015, Accepted 05 Oct 2015, Published online: 07 Nov 2015

References

  • Aggarwal P, Hall JB, McLeland CB, et al. (2009). Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy. Adv Drug Deliv Rev 61:428–37
  • Barichello JM, Morishita M, Takayama K, Nagai T. (1999). Encapsulation of hydrophilic and lipophilic drugs in PLGA nanoparticles by the nanoprecipitation method. Drug Dev Ind Pharm 25:471–6
  • Beretta GL, Zunino F. (2007). Relevance of extracellular and intracellular interactions of camptothecins as determinants of antitumor activity. Biochem Pharmacol 74:1437–44
  • Bilati U, Allémann E, Doelker E. (2005). Poly(D,L-lactide-co-glycolide) protein-loaded nanoparticles prepared by the double emulsion method-processing and formulation issues for enhanced entrapment efficiency. J Microencapsul 22:205–14
  • Bodmeier R, McGinity J. (1988). Solvent selection in the preparation of poly (DL-lactide) microspheres prepared by the solvent evaporation method. Int J Pharm 43:179–86
  • Brave M, Dagher R, Farrell A, et al. (2006). Topotecan in combination with cisplatin for the treatment of stage IVB, recurrent, or persistent cervical cancer. Oncology 20:1401–15
  • Brendel ML, Sandler SI. (1999). The effect of salt and temperature on the infinite dilution activity coefficients of volatile organic chemicals in water. Fluid Phase Equilibria 165:87–97
  • Chorny M, Fishbein I, Danenberg HD, Golomb G. (2002). Lipophilic drug loaded nanospheres prepared by nanoprecipitation: effect of formulation variables on size, drug recovery and release kinetics. J Control Release 83:389–400
  • Ci T, Li T, Chang G, et al. (2012). Simply mixing with poly (ethylene glycol) enhances the fraction of the active chemical form of antitumor drugs of camptothecin family. J Control Release 169:329–35
  • Dilnawaz F, Singh A, Mohanty C, Sahoo SK. (2010). Dual drug loaded superparamagnetic iron oxide nanoparticles for targeted cancer therapy. Biomaterials 31:3694–706
  • Dufort S, Sancey L, Coll JL. (2012). Physico-chemical parameters that govern nanoparticles fate also dictate rules for their molecular evolution. Adv Drug Deliv Rev 64:179–89
  • Dunne M, Corrigan O, Ramtoola Z. (2010). Influence of particle size and dissolution conditions on the degradation properties of polylactide- co-glycolide particles. Biomaterials 21:1659–68
  • Faraji AH, Wipf P. (2009). Nanoparticles in cellular drug delivery. Bio-org Med Chem 17:2950–62
  • Fonseca C, Simoes S, Gaspar R. (2002). Paclitaxel-loaded PLGA nanoparticles: preparation, physicochemical characterization and in vitro anti-tumoral activity. J Control Release 83:273–86
  • Gibaldi M, Feldman S. (1967). Establishment of sink conditions in dissolution rate determinations. Theoretical considerations and application to nondisintegrating dosage forms. J Pharm Sci 56:1238–42
  • Grant DJ, Higuchi T. (1990). Solubility behavior of organic compounds. New York: John Wiley and Sons
  • Higuchi T. (1961). Rate of release of medicaments from ointment bases containing drugs in suspension. J Pharm Sci 50:874–5
  • Jain S, Mittal AK, Jain A, et al. (2010). Cyclosporin A loaded PLGA nanoparticle: preparation, optimization, in-vitro characterization and stability studies. Curr Nanosci 6:422–31
  • Jiang G, Thanoo B, DeLuca PP. (2002). Effect of osmotic pressure in the solvent extraction phase on BSA release profile from PLGA microspheres. Pharm Dev Technol 7:391–9
  • Jiao Y, Ubrich N, Marchand-Arvier M, et al. (2002). In vitro and in vivo evaluation of oral heparin–loaded polymeric nanoparticles in rabbits. Circulation 105:230–5
  • Korsmeyer RW, Gurny R, Doelker E. (1983). Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm 15:25–35
  • Li X, Deng X, Yuan M, et al. (1999). Investigation on process parameters involved in preparation of poly-dl-lactide-poly (ethylene glycol) microspheres containing Leptospira Interrogans antigens. Int J Pharm 178:245–55
  • Mirza MA, Ahmad N, Agarwal SP, et al. (2011). Comparative evaluation of humic substances in oral drug delivery. Results Pharma Sci 1:16–26
  • Mirza M, Talegaonkar S, Iqbal Z. (2012). Particle engineering in the perspective of thermodynamics: a case study with itraconazole. Adv Sci Lett 16:148–58
  • Mishra N, Tiwari S, Vaidya B, et al. (2011). Lectin anchored PLGA nanoparticles for oral mucosal immunization against hepatitis B. J Drug Target 19:67–78
  • Misra R, Sahoo SK. (2010). Intracellular trafficking of nuclear localization signal conjugated nanoparticles for cancer therapy. Eur J Pharm Sci 39:152–63
  • Nicum SJ, O’Brien ME. (2007). Topotecan for the treatment of small-cell lung cancer. Expert Rev Anticancer Ther 7:795–801
  • Opanasopit P, Yokoyama M, Watanabe W, et al. (2005). Influence of serum and albumins from different species on stability of camptothecin-loaded micelles. J Control Release 104:313–21
  • Panagi Z, Beletsi A, Evangelatos G, et al. (2001). Effect of dose on the biodistribution and pharmacokinetics of PLGA and PLGA–mPEG nanoparticles. Int J Pharm 221:143–52
  • Quintanar-Guerrero D, Fessi H, Allemann E, Doelker E. (1996). Influence of stabilizing agents and preparative variables on the formation of poly (D,L-lactic acid) nanoparticles by an emulsification-diffusion technique. Int J Pharm 143:133–41
  • Rafati H, Coombes A, Adler J, et al. (1997). Protein-loaded poly (DL-lactide-co-glycolide) microparticles for oral administration: formulation, structural and release characteristics. J Control Release 43:89–102
  • Sahoo SK, Ma W, Labhasetwar V. (2004). Efficacy of transferring-conjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer. Int J Cancer 112:335–40
  • Sahoo SK, Parveen S, Panda JJ. (2007). The present and future of nanotechnology in human health care. Nanomedicine 3:20–31
  • Sanders E, Ashworth CT. (1961). A study of particulate intestinal absorption and hepatocellular uptake. Exp Cell Res 22:137–45
  • Varelas CG, Dixon DG, Steiner CA. (1995). Zero-order release from biphasic polymer hydrogels. J Control Release 34:185–92
  • Wethington SL, Wright JD, Herzog TJ. (2008). Key role of topoisomerase I inhibitors in the treatment of recurrent and refractory epithelial ovarian carcinoma. Expert Rev Anticancer Ther 8:819–31
  • FreieUniversität Berlin. (2006). Cyclosporine nanosuspensions. Available at: http://www.diss.fuberlin.de/diss/servlets/MCRFileNodeServlet/FUDISS_derivate_000000002344/06_7Chapter7.pdf?hosts=[last accessed 27 Oct 2015]
  • Yu Y, Wang Z-H, Zhang L, et al. (2012). Mitochondrial targeting topotecan-loaded liposomes for treating drug-resistant breast cancer and inhibiting invasive metastases of melanoma. Biomaterials 33:1808–20

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.